Align Technology (NASDAQ: ALGN) and OraSure Technologies (NASDAQ:OSUR) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, dividends and profitabiliy.

Volatility and Risk

Align Technology has a beta of 1.55, suggesting that its share price is 55% more volatile than the S&P 500. Comparatively, OraSure Technologies has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500.

Profitability

This table compares Align Technology and OraSure Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Align Technology 19.18% 23.87% 16.93%
OraSure Technologies 22.29% 15.64% 13.88%

Earnings & Valuation

This table compares Align Technology and OraSure Technologies’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Align Technology $1.24 billion 10.95 $305.54 million $2.92 57.98
OraSure Technologies $135.07 million 8.92 $23.80 million $0.54 38.16

Align Technology has higher revenue and earnings than OraSure Technologies. OraSure Technologies is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Align Technology and OraSure Technologies, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Align Technology 0 0 9 0 3.00
OraSure Technologies 0 1 5 0 2.83

Align Technology presently has a consensus price target of $179.00, suggesting a potential upside of 5.73%. OraSure Technologies has a consensus price target of $15.04, suggesting a potential downside of 27.00%. Given Align Technology’s stronger consensus rating and higher probable upside, analysts plainly believe Align Technology is more favorable than OraSure Technologies.

Institutional and Insider Ownership

87.3% of Align Technology shares are owned by institutional investors. Comparatively, 89.9% of OraSure Technologies shares are owned by institutional investors. 2.0% of Align Technology shares are owned by company insiders. Comparatively, 7.8% of OraSure Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Align Technology beats OraSure Technologies on 10 of the 14 factors compared between the two stocks.

About Align Technology

Align Technology, Inc. designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and computer-aided design/computer-aided manufacturing (CAD/CAM) digital services used in dentistry, orthodontics and dental records storage. The Company operates through two segments: Clear Aligner segment and Scanner and Services (Scanner) segment. The Clear Aligner segment consists of its Invisalign System, which includes Invisalign Full, Teen and Assist (Comprehensive Products), Express/Lite (Non-Comprehensive Products) and Vivera Retainers, along with its training and ancillary products for treating malocclusion (Non-Case). The Scanner segment consists of intra-oral scanning systems and other services available with the intra-oral scanners that provide digital alternatives to the traditional cast models. The Scanner segment includes its iTero scanner and OrthoCAD services.

About OraSure Technologies

OraSure Technologies, Inc. (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The Company operates in two segments: OSUR and DNAG. OSUR consists of the development, manufacture and sale of diagnostic products, specimen collection devices, and medical devices. DNAG or molecular collection systems business consists primarily of the development, manufacture and sale of oral fluid collection devices that are used to collect, stabilize, and store samples of genetic material for molecular testing. It also manufactures and sells medical devices used for the removal of benign skin lesions by cryosurgery or freezing. It sells over-the-counter (OTC) cryosurgical products to consumers in North America, Europe, Central and South America, and Australia.

Receive News & Ratings for Align Technology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.